This guidance is a Cancer Drugs Fund reconsideration of pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309) and replaces this guidance. It was previously available through the Cancer Drugs Fund, but will now be routinely available on the NHS because the company that markets it has lowered the price and so it is now considered better value for money.